BioDuro is expanding its global contract research, development, and manufacturing organization (CRDMO) network with the opening of a new drug substance R&D and manufacturing campus in Bengbu, China. This move, set to begin operations in September 2025, is part of the company’s strategy to strengthen its drug substance manufacturing capabilities, particularly for large-scale commercial production of regulatory starting material (RSM).

In addition to the new campus, BioDuro is enhancing its Shanghai campuses with high-potency labs and peptide scale-up synthesis facilities. These upgrades are designed to increase the company’s capacity to meet the growing demand for scalable, integrated solutions in the biopharmaceutical industry, particularly for small molecules, peptides, and complex conjugated drugs.

The Bengbu campus will feature a total reactor volume of 130,000 liters distributed across eight manufacturing lines, with individual reactors reaching up to 15,000 liters. This large capacity will enable the company to support drug substance projects from Phase I clinical trials through to commercial supply. The campus will also house an integrated process R&D centre that will accommodate more than 150 chemists, allowing for efficient process development, optimization, and scale-up. This setup is designed to facilitate smooth technology transfer and project execution, ensuring that the company can meet the increasing demand for drug substance manufacturing as pharmaceutical projects progress toward commercialization.

BioDuro’s investment in these facilities underscores its commitment to expanding its global presence and offering robust solutions to support the growth of the biopharmaceutical sector.

For more details please visit our website - https://www.medhealthinsight.com/bioduro-launches-new-rd-and-manufacturing-campus-in-china-for-biopharma/